论文部分内容阅读
采用同种异体 LAK(Allogeneic-LAK,Allo-LAK)细胞代替患者自身LAK细胞,较好地解决了LAK细胞前体来源问题.通过超声雾化吸入及胸腔内注射Allo-LAK/IL-2治疗肺癌能改善肿瘤微环境,激活肿瘤局部免疫细胞抑制肿瘤细胞,并且较好地解决了Allo-LAK的安全性,避免了大剂量应用IL-2所致的毒副作用.1 材料与方法1.1 病例选择临床确诊为晚期肺癌不能手术切除的14例病人,其中男10例,女4例,年龄39～68岁,平均57.64岁.均经病理或组织细胞学检查确诊为鳞癌7例,腺癌5例,小细胞未分化癌(SCLC)2例,8例并发胸腔积液,4例并发对侧肺转移,3例并发纵隔及锁骨上淋巴结转移,另有2例及1例分别并发骨及肝转移.
The allogeneic LAK (Allo-LAK) cells were used instead of the patient’s own LAK cells to better solve the source problem of LAK cell precursors. It was treated by ultrasonic atomization inhalation and intrapleural injection of Allo-LAK/IL-2. Lung cancer can improve the tumor microenvironment, activate tumor local immune cells to inhibit tumor cells, and better solve the safety of Allo-LAK, and avoid the toxic side effects caused by high-dose application of IL-2.1 Materials and methods 1.1 Case selection Clinically diagnosed as advanced lung cancer can not be surgically removed in 14 patients, including 10 males and 4 females, aged 39 to 68 years, mean 57.64 years old. All were confirmed by pathology or histological examination of squamous cell carcinoma in 7 cases, adenocarcinoma 5 Cases, 2 cases of small cell undifferentiated carcinoma (SCLC), 8 cases of pleural effusion, 4 cases of contralateral lung metastasis, 3 cases of mediastinal and supraclavicular lymph node metastases, 2 cases and 1 case of concurrent bone and liver Transfer.